Sudo Biosciences Appoints Paul Bavier as Chief Legal Counsel
Sudo Biosciences, (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the appointment of Paul S. Bavier, J.D., as Chief Legal Officer.
Sudo Biosciences Announces Positive Phase 1 Results for Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550
Sudo Biosciences, (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced positive topline results from its Phase 1 first-in-human clinical trial of SUDO-550, an oral, CNS-penetrant, allosteric TYK2 inhibitor for the treatment of neuroinflammatory diseases. The study evaluated single and multiple ascending doses of SUDO-550 in healthy volunteers, including participants aged 65 and older.
Sudo Biosciences Announces First Participants Dosed in Phase 1 Trial of Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550
Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, announced today that the first participants have been dosed in a Phase 1 clinical trial evaluating SUDO-550, a novel brain-penetrant allosteric TYK2 inhibitor for the treatment of neuroinflammatory diseases.
Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M
Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced that during January 2024, it completed a second close of its Series B financing, raising an additional $30 million from new investors Dementia Discovery Fund (DDF, a SV Health Investors Fund), Leaps by Bayer, and UPMC Enterprises, the innovation, commercialization and venture capital arm of UPMC. This brings the total raised in this upsized round to $147 million.
Sudo Biosciences Raises $116M Series B Financing to Advance Potential Best-in-Class TYK2 Therapeutics Programs into the Clinic
Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the close of a $116 million Series B financing round co-led by Enavate Sciences and TPG, which is investing in the company through TPG Life Sciences Innovations and The Rise Fund, with participation from Sanofi Ventures, Surveyor Capital (a Citadel company), Monograph Capital, and Eventide Asset Management as well as existing investors Frazier Life Sciences and Velosity Capital. The Company has raised a total of $157 million funding since its founding in 2020.
Sudo Biosciences Appoints Imran Babar, Ph.D., as Chief Business Officer
Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing a broad pipeline of best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the appointment of Imran Babar, Ph.D., as chief business officer. Dr. Babar is an accomplished industry leader with broad experience in healthcare strategy, life sciences finance, operations and business development.
Sudo Biosciences Raises $37M Series A Financing to Advance Precision TYK2 Therapeutics
Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing a broad pipeline of best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced the close of $37M in Series A financing led by Frazier Life Sciences (“Frazier”) and Velosity Capital. The Series A funding will be used primarily to advance Sudo’s lead drug candidates into the clinic.
